Status: Recruiting
A Study of CSTI-500 in Patients With Prader-Willi Syndrome
This is a proof-of-concept, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CSTI-500 in participants with genetically confirmed Prader-Willi Syndrome (PWS) who are 13 to 50 years of age. Participants will receive increasing doses of CSTI-500, and blood levels will be measured to guide individualized dosing.
Participants needed: 12
Trial details
Phase: Phase 2Age: 13-50Biological sex: AllType: InterventionalSponsor: ConSynance TherapeuticsUpdated: May 15, 2026Locations: 1
Eligibility criteria
Generally healthy male and female individuals between the ages of 13 and 50, inc... [+17]
Participation in any clinical study with an investigational drug/device within 3... [+27]